Protein detail
PTAFR
Platelet-activating factor receptor (PAF-R) (PAFr)
Entry name PTAFR | UniProt ID | EVMP confidence score 0.50 |
Supporting publications (n) 2 | Transmembrane count 7 | Protein classification FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteinsTransporters |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information12
Protein Names
Platelet-activating factor receptor (PAF-R) (PAFr)
Protein Class (4)
FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteinsTransporters
Protein Function (3)
- Transporters
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Transmembrane
17..38; Helical; Name=1; 55..74; Helical; Name=2; 92..113; Helical; Name=3; 134..155; Helical; Name=4; 185..205; Helical; Name=5; 234..254; Helical; Name=6; 277..296; Helical; Name=7
Transmembrane Count
7
Ensembl
Entrez Gene Symbol
Gene Description
Platelet activating factor receptor
Chromosome
1
Position
28147166-28193936
Supporting publications (n)
2
EVMP confidence score
0.50
Fluorescence & Localization6
Tissue Specificthyroid glandCell SpecificChoroid plexus epithelial cellsSingle-Nuclei Brain Specificchoroid plexus epithelial cellBlood Cell SpecificneutrophilBlood Lineage Specificgranulocytes
Function & Pathway7
Protein Function (3)
- Transporters
- FDA approved drug targets:Small molecule drugs
- G-protein coupled receptors:GPCRs excl olfactory receptors
Cellular Component (4)
Molecular Function (8)
- GO:0001530 lipopolysaccharide binding
- GO:0001875 lipopolysaccharide immune receptor activity
- GO:0004930 G protein-coupled receptor activity
- GO:0004992 platelet activating factor receptor activity
- GO:0005515 protein binding
- GO:0005543 phospholipid binding
- GO:0045028 G protein-coupled purinergic nucleotide receptor activity
- GO:0051019 mitogen-activated protein kinase binding
Biological Process (3)
KEGG (3)
Reactome (11)
- R-hsa-373076 class a 1 rhodopsin like receptors
- R-hsa-1280215 cytokine signaling in immune system
- R-hsa-500792 gpcr ligand binding
- R-hsa-416476 g alpha q signalling events
- R-hsa-168249 innate immune system
- R-hsa-877300 interferon gamma signaling
- R-hsa-913531 interferon signaling
- R-hsa-6783783 interleukin 10 signaling
- R-hsa-6798695 neutrophil degranulation
- R-hsa-372790 signaling by gpcr
Page 1 of 2
Mediation Categories (5)
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationReceptor-signaling mediation
Relations & Evidence61
Ligand-Receptor Signaling (47)
47 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| intracellular | intracellular | OmniPath | No | No | No | Yes | No |
| cell_adhesion | cell_adhesion | Cellinker | Yes | Yes | No | Yes | No |
| adhesion | adhesion | OmniPath | Yes | Yes | No | Yes | No |
| cell_adhesion | cell_adhesion | OmniPath | Yes | Yes | No | Yes | No |
| transmembrane | transmembrane | UniProt_location | No | No | No | Yes | No |
| transmembrane | transmembrane | UniProt_topology | No | No | No | Yes | No |
| transmembrane | transmembrane | UniProt_keyword | No | No | No | Yes | No |
| transmembrane | transmembrane | GO_Intercell | No | No | No | Yes | No |
| transmembrane | transmembrane | TopDB | No | No | No | Yes | No |
| transmembrane | transmembrane | LOCATE | No | No | No | Yes | No |
Regulatory Interaction Network (11)
11 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| PTAFR | P25105 | GNA14 | O95837 | Yes | Yes | No | WangSIGNOR | SIGNOR:31160049 |
Page 2 of 2Previous
Protein Complex Composition (2)
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential Ultracentrifugation | Western blottingImmunofluorescence | 1 | 38795909 |
Sequence, Structure & Domains9
Sequences
Length
342
Mass
39,203
Sequence
MEPHDSSHMDSEFRYTLFPIVYSIIFVLGVIANGYVLWVFARLYPCKKFNEIKIFMVNLTMADMLFLITLPLWIVYYQNQGNWILPKFLCNVAGCLFFINTYCSVAFLGVITYNRFQAVTRPIKTAQANTRKRGISLSLVIWVAIVGAASYFLILDSTNTVPDSAGSGNVTRCFEHYEKGSVPVLIIHIFIVFSFFLVFLIILFCNLVIIRTLLMQPVQQQRNAEVKRRALWMVCTVLAVFIICFVPHHVVQLPWTLAELGFQDSKFHQAINDAHQVTLCLLSTNCVLDPVIYCFLTKKFRKHLTEKFYSMRSSRKCSRATTDTVTEVVVPFNQIPGNSLKN
3D Structural Models
Turn
79..81; 179..181
Helix
5..10; 14..43; 47..49; 50..67; 70..78; 87..119; 122..126; 142..154; 184..214; 224..243; 245..260; 265..282; 285..312
Beta Strand
158..162; 164..174
3D Structure
Electron microscopy (1); X-ray crystallography (2)
Domain & Motif Annotations
Protein Families
G-protein coupled receptor 1 family
Sequence Similarities
Belongs to the G-protein coupled receptor 1 family.
Clinical Relevance9
Disease Involvement
FDA approved drug targets
Related Diseases (18)
Allergic/hypersensitivity disorderAsthmaCardiac arrhythmiaCerebral ischaemiaCerebral ischaemic strokeConjunctiva disorderDengue feverHepatitis virus infectionIndeterminate colitisIschaemic/haemorrhagic strokeObesityPostoperative inflammationPsoriasisSepsisSolid tumour/cancerThrombocytopeniaThrombosisUnspecific body region injury
Biomarker
Discontinued in Phase 1; Phase 3; Terminated; Investigative; Discontinued in Phase 2; Phase 2; Approved; Phase 1
Drug Targets
FDA approved drug targets
Antibody
Interaction Protein (2)
ENSG00000171867ENSG00000197971
Interaction Count
2
Interaction Dataset
intact_biogrid
Supporting Publications2
| PMID | Title | Abstract |
|---|---|---|
| 36146834 | Human Cytomegalovirus Modifies Placental Small Extracellular Vesicle Composition to Enhance Infection of Fetal Neural Cells In Vitro. | No abstract available |
| 38207106 | Proteomic, Metabolomic, and Fatty Acid Profiling of Small Extracellular Vesicles from Glioblastoma Stem-Like Cells and Their Role in Tumor Heterogeneity. | No abstract available |